By Susan Van Dusen
The Phase 1 clinical trial of the novel vaccine, developed by Kieber-Emmons at the UAMS Winthrop P. Rockefeller Cancer Institute, is showing promising results.
“The Phase 1 trial is to demonstrate the safety and tolerability of the drug using a small group of participants,” he said. The participants are selected by Kieber-Emmons’ fellow researcher and UAMS medical oncologist Laura Hutchins, M.D., and must meet a strict set of criteria to qualify.
The women receive five injections of the vaccine during a 23-week span. So far, none have experienced adverse reactions. “We are optimistic about the results in our trial participants,” he said.
After the Phase 1 trial is complete and shown to meet the safety and tolerability requirements, a Phase 2 trial will begin to examine the quality of the immune response in humans. This trial will include a larger number of women who were previously treated for breast cancer but are now disease free.
Kieber-Emmons is professor of pathology in the UAMS College of Medicine and holder of the Josetta Wilkins Chair of Breast Cancer Research.